購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
B6-Mmut*M698K/Mmut KO Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
B6-Mmut*M698K/Mmut KO Mouse
製品名
B6-Mmut*M698K/Mmut KO Mouse
製品ID
C001828
系統名
C57BL/6JCya-Mmutem1/Mmutem2(M698K)/Cya
背景情報
C57BL/6JCya
状況
このマウス系統を論文で使用する場合は、「B6-Mmut*M698K/Mmut KO Mouse(カタログ番号C001828)はサイアジェンから購入しました。」と引用してください。
Disease Animal Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Disease Animal Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
Mcm, Mut, D230010K02Rik
NCBI ID
染色体
Chr 17
MGI ID
さらに
系統詳細
The Mmut gene encodes the mitochondrial enzyme methylmalonyl-CoA mutase (MCM), a protein critical for the metabolism of specific amino acids and fatty acids, cholesterol catabolism, and energy production. This gene is widely expressed, with particularly high levels in the liver and kidney. Mutations in Mmut cause methylmalonic acidemia (MMA), a severe autosomal recessive genetic disorder characterized by the accumulation of methylmalonic acid in blood and urine, which triggers life-threatening metabolic crises, developmental delay, and progressive renal failure. The refractoriness of this condition to conventional dietary and pharmacological management has led some patients to undergo elective liver transplantation (LT) or combined liver-kidney transplantation (LKT) to maintain metabolic stability. While LT or LKT reduces the risk of metabolic decompensation, post-transplant patients still exhibit biochemical abnormalities such as elevated methylmalonic acid levels in blood and cerebrospinal fluid. Patients receiving liver transplantation alone remain at risk of renal insufficiency, basal ganglia damage, and optic neuropathy. Additionally, long-term immunosuppressive therapy post-transplant may induce toxic reactions and increase the risk of malignancy [1-2]. Current therapeutic strategies for MMA focus on developing drugs that enhance MCM activity or bypass metabolic blocks, including chaperone therapy to improve protein folding and stability, enzyme replacement therapy, and gene therapy strategies to deliver functional Mmut gene copies [3-4].
B6-Mmut*M698K/Mmut KO mice are a MMA disease model generated by crossing Mmut-knockout mice (with exon 3 deleted) with Mmut-mutant mice (carrying the p.M698K mutation in exon 12). Homozygous deletion of the gene results in embryonic lethality, and homozygous mutant mice die within 1 day of birth. The p.M698K (ATG to AAG) mutation carried by B6-Mmut*M698K/Mmut KO mice is equivalent to the p.M700K (ATG to AAG) mutation in the human MMUT gene. This model can be used to study the pathogenic mechanisms and therapeutic approaches for MMA.
参考文献
Head PE, Meier JL, Venditti CP. New insights into the pathophysiology of methylmalonic acidemia. J Inherit Metab Dis. 2023 May;46(3):436-449.
Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, Huemer M, Hochuli M, Assoun M, Ballhausen D, Burlina A, Fowler B, Grünert SC, Grünewald S, Honzik T, Merinero B, Pérez-Cerdá C, Scholl-Bürgi S, Skovby F, Wijburg F, MacDonald A, Martinelli D, Sass JO, Valayannopoulos V, Chakrapani A. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014 Sep 2;9:130.
Haijes HA, van Hasselt PM, Jans JJM, Verhoeven-Duif NM. Pathophysiology of propionic and methylmalonic acidemias. Part 2: Treatment strategies. J Inherit Metab Dis. 2019 Sep;42(5):745-761.
Venturoni LE, Venditti CP. Treatment of metabolic disorders using genomic technologies: Lessons from methylmalonic acidemia. J Inherit Metab Dis. 2022 Sep;45(5):872-888.
系統作製戦略
The exon 3 region of the mouse Mmut gene is knocked out using gene editing technology.
The p.M698K (ATG to AAG) mutation is introduced into exon 12 of the mouse Mmut gene using gene editing technology.

Figure 1. Gene editing strategy for Mmut knockout (Mmut KO) mice.

Figure 2. Gene editing strategy for Mmut mutant mice (Mmut*M698K).
適用分野
Research on the pathogenic mechanisms and therapeutic approaches of methylmalonic acidemia (MMA);
Research on the mechanisms of other mitochondrial metabolic diseases;
Research on the mechanisms of neurological damage;
Research on the mechanisms and therapeutic strategies of kidney diseases.
検証 Data
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
